1. Home
  2. IMRN vs GIPR Comparison

IMRN vs GIPR Comparison

Compare IMRN & GIPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMRN
  • GIPR
  • Stock Information
  • Founded
  • IMRN 1994
  • GIPR 2015
  • Country
  • IMRN Australia
  • GIPR United States
  • Employees
  • IMRN N/A
  • GIPR N/A
  • Industry
  • IMRN Biotechnology: Pharmaceutical Preparations
  • GIPR Real Estate Investment Trusts
  • Sector
  • IMRN Health Care
  • GIPR Real Estate
  • Exchange
  • IMRN Nasdaq
  • GIPR Nasdaq
  • Market Cap
  • IMRN 9.2M
  • GIPR 7.7M
  • IPO Year
  • IMRN N/A
  • GIPR 2021
  • Fundamental
  • Price
  • IMRN $1.72
  • GIPR $1.42
  • Analyst Decision
  • IMRN Strong Buy
  • GIPR
  • Analyst Count
  • IMRN 1
  • GIPR 0
  • Target Price
  • IMRN $5.00
  • GIPR N/A
  • AVG Volume (30 Days)
  • IMRN 656.2K
  • GIPR 23.5K
  • Earning Date
  • IMRN 09-08-2025
  • GIPR 08-14-2025
  • Dividend Yield
  • IMRN N/A
  • GIPR N/A
  • EPS Growth
  • IMRN N/A
  • GIPR N/A
  • EPS
  • IMRN N/A
  • GIPR N/A
  • Revenue
  • IMRN $4,048,286.00
  • GIPR $9,711,058.00
  • Revenue This Year
  • IMRN N/A
  • GIPR N/A
  • Revenue Next Year
  • IMRN N/A
  • GIPR N/A
  • P/E Ratio
  • IMRN N/A
  • GIPR N/A
  • Revenue Growth
  • IMRN 82.90
  • GIPR 11.25
  • 52 Week Low
  • IMRN $1.50
  • GIPR $1.33
  • 52 Week High
  • IMRN $2.87
  • GIPR $3.10
  • Technical
  • Relative Strength Index (RSI)
  • IMRN 45.31
  • GIPR 44.59
  • Support Level
  • IMRN $1.60
  • GIPR $1.38
  • Resistance Level
  • IMRN $1.80
  • GIPR $1.48
  • Average True Range (ATR)
  • IMRN 0.10
  • GIPR 0.07
  • MACD
  • IMRN -0.01
  • GIPR -0.00
  • Stochastic Oscillator
  • IMRN 34.09
  • GIPR 19.90

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

About GIPR Generation Income Properties Inc.

Generation Income Properties Inc is an internally managed real estate investment company focused on acquiring and managing income-producing retail, office and industrial properties net leased to high-quality tenants in markets throughout the United States. Its key source of revenue is the rental income. The company holds properties in Alabama, Arizona, Colorado, the District of Columbia, Florida, Illinois, North Carolina and Virginia.

Share on Social Networks: